Vertex Pharmaceuticals (VRTX) Leases (2009 - 2026)

Vertex Pharmaceuticals has reported Leases for 17 years, with the latest figure at $1.7 billion in Q1 2026.

• For the quarter ending Q1 2026, Leases rose 25.89% year-over-year to $1.7 billion; the trailing twelve-month figure through Mar 2026 stood at $1.7 billion (up 25.89% YoY), and the FY2025 full-year result was $1.6 billion, up 15.18% from the prior year.
• Leases for Q1 2026 stood at $1.7 billion, up from $1.6 billion in the prior quarter.
• The five-year high for Leases was $1.7 billion in Q1 2026, with the low at $293.6 million in Q4 2023.
• Average Leases over 5 years is $805.7 million, with a median of $342.7 million recorded in 2022.
• Year-over-year, Leases fell 21.14% in 2022 and soared 362.13% in 2024.
• Tracing VRTX's Leases over 5 years: stood at $315.5 million in 2022, then decreased by 6.94% to $293.6 million in 2023, then soared by 362.13% to $1.4 billion in 2024, then increased by 15.18% to $1.6 billion in 2025, then advanced by 7.83% to $1.7 billion in 2026.
• The last three Leases figures came in at $1.7 billion (Q1 2026), $1.6 billion (Q4 2025), and $1.6 billion (Q3 2025), per Business Quant data.

Peer Comparison